Articles

The long and short reads of it

Illumina aims at a more comprehensive sequencing offering with the acquisition of PacBio
Written byKelsey Kaustinen
| 3 min read

SAN DIEGO & MENLO PARK, Calif.—Illumina Inc. is going to face the coming new year with new growth, having announced an agreement under which it will acquire Pacific Biosciences for $8 per share in an all-cash transaction. Both companies’ boards of directors have approved the deal, which has a total enterprise value of roughly $1.2 billion on a fully diluted basis.

That price represents a 71-percent premium over PacBio’s 30-day trading volume weighted average share price as of Oct. 31, the day before the transaction was made public. The acquisition is expected to close by mid-2019, pending shareholder approval on the part of Pacific Biosciences, regulatory approval and other customary closing conditions.

As noted by Francis deSouza, president and CEO of Illumina, this is the company’s largest acquisition since it absorbed Solexa in 2007.

To continue reading this article, subscribe for FREE toDrug Discovery News Logo

Subscribe today to keep up to date with the latest advancements and discoveries in drug development achieved by scientists in pharma, biotech, non-profit, academic, clinical, and government labs.

Add Drug Discovery News as a preferred source on Google

Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.

About the Author

Here are some related topics that may interest you:

Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Gloved hand holding a multiwell cell culture plate under a fluorescence microscope for spheroid analysis.
Using confocal live-cell imaging to characterize immune-mediated cytotoxicity over time.
Fluorescence microscopy image of cells displaying green and red fluorescent signals.
Using confocal live-cell imaging to assess treatment effects in spheroids, organoids, and co-cultures.
3D illustration of Y-shaped antibody molecules floating against a soft blue background, with a detailed antibody structure in the foreground.
From molecular developability to functional activity, integrated characterization strategies help inform lead selection and optimization in biologics discovery.